AKL

AKL Research and Development is a clinical-stage pharmaceutical company based in the United Kingdom, dedicated to developing innovative treatments for inflammatory and degenerative diseases. The company's primary focus is on osteoarthritis, where it is advancing its lead oral candidate, APPA, a synthetic fixed-dose combination of two secondary metabolites. APPA works by modulating the inflammatory response through the NF-kappaB and Nrf2 pathways, offering a potential disease-modifying approach rather than just symptomatic relief. AKL's research strategy involves identifying and optimizing molecules derived from natural sources to address significant unmet needs in chronic pain and inflammation.